ArticleJournal of cosmetic dermatology2025
Efficacy and Effectiveness of High Molecular Weight Non-Cross-Linked Hyaluronic Acid Plus Succinic Acid Mesotherapy in Rosacea as Adjunct Therapy.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Refractory Stasis Dermatitis Due to Chronic Venous Insufficiency With Psychosocial Worsening in 2 Septuagenarian Patients Treated With Hyaluronic Acid-Succinic Acid Intradermotherapy.The American journal of case reports · 2026Article
- The PATH Protocol for Integrated Facial Rejuvenation: A Preliminary Three-Patient Case Report Series and Narrative Review of the Literature.Reports (MDPI) · 2026Article
- Effect of Supine Versus Sitting Positions on Facial Tissue Dielectric Constant Values in Young Adult Men.Cureus · 2026Article
- Hyaluronic Acid, Succinic Acid, and Exosomes in the Treatment of Facial Hyperpigmentation: A Report of Two Cases.Cureus · 2026Article
- A Prospective, Multicenter, Randomized, Assessor-Blinded Study Assessing the Efficacy and Safety of Injectable Non-Cross-Linked Hyaluronic Acid for Improving Facial Skin Rejuvenation.Clinical, cosmetic and investigational dermatology · 2026Article
- Efficacy and Effectiveness of High Molecular Weight Non-Cross-Linked Hyaluronic Acid Plus Succinic Acid Mesotherapy in Rosacea as Adjunct Therapy.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRosacea is a highly prevalent dermatosis affecting 5% of the world's population. Its impact is not only physical but also psychological, as over 60% of patients with rosacea also suffer from depression, anxiety, and other psychological comorbidities. Currently, topical treatments yield low or unsatisfactory success rates, and rosacea complications such as disfigurement, burning sensation, and pain can greatly affect patients' well-being. Intra-dermotherapy with high molecular weight non-cross-linked hyaluronic acid plus succinic acid has shown anti-inflammatory, regenerative, and vascular modulatory effects.
objectivesTo evaluate the efficacy and effectiveness of high molecular weight non-cross-linked hyaluronic acid (HMWNCHA) plus succinic acid (SA) mesotherapy in rosacea patients who are not responding to topical treatments. To determine the degree of improvement in general parameters such as erythema, telangiectasia, and skin laxity and hydration. To compare the cost of this treatment with that of laser therapy, a widely used modality.
methodsWe performed a non-randomized, controlled interventional study, and we evaluated the results after three sessions (once monthly) as the primary endpoint of this mesotherapy, using a product containing 1.1% of high molecular weight non-cross-linked hyaluronic acid plus 1.6% succinic acid (full face, 2 mL per session, administered using the papule technique) in a group of 20 male and female patients, aged 40-45 years, Fitzpatrick skin types I-III, without comorbidities. All patients were already undergoing topical treatment with Ivermectin 1%, Metronidazole 0.75%, and photoprotection, but without good results or clear improvement, quantified as a reduction in the Investigator's Global Assessment (IGA) severity score of at least 1 point. Erythema, hydration, and facial telangiectasia were evaluated at every session for proper quantification. Our study group was compared with a control group that only continued their topical treatment, and the study lasted 4 months, with a prospective follow-up at 6 months.
resultsOur results showed a reduction of 80% in the baseline erythema, an improvement of 30% in skin hydration, and a reduction of 20% in facial telangiectasia after three sessions, compared with patients who used only topical treatment. In addition, the costs were significantly lower than those of three sessions of laser therapy in a private healthcare setting.
conclusionWe demonstrated that using this acid combination in mesotherapy is an efficient, safe, and cost-effective adjunct therapy for patients already using a particular topical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.